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a b s t r a c t
Background: Antiretroviral therapy (ART) saved millions from HIV-1 infection and AIDS, but
some patients do not experience adequate CD4+ T cells gain despite achieving viral sup-
pression. The genetic component of this condition is not yet completely elucidated.
Objective: To identify predictive genetic markers of immune response to ART.
Methods: Case–control study. Out of 176 HIV-infected patients recruited in the city of Recife,
Northeast Brazil, 67 patients with no immunologic response were the cases and the remain-
ing 109 patients who responded were the controls. A set of 94 selected single nucleotide
polymorphisms (SNPs) involved in antiretroviral drugs pharmacodynamic pathways and
immune system homeostasis were genotyped, while the remaining 48 were ancestry infor-
mative markers (AIMs) for controlling for eventual hidden population structure.
Results: Male patients were overrepresented in non-responder group (p=0.01). Non-
responders also startedwith lower absoluteCD4+T cell counts (p<0.001).We foundfive SNPs
significantly associated with the outcome, being three more frequent in non-responders
than responders: rs2243250 (IL4) A allele (p=0.04), rs1128503 (ABCB1) A allele (p=0.03) and
rs707265 (CYP2B6) A allele (p=0.02), whereas the other two were less frequent in non-
responders: rs2069762 (IL2) C allele (p=0.004) and rs4646437 (CYP3A4) A allele (p=0.04).
Conclusion: Some significant univariate associations remained independently associated at
multivariate survival analysis modeling, such as pre-treatment CD4+ T cells counts, IL2
and ABCB1 genotypes, and use of protease inhibitors, yielding a predictive model for the
probability for immune response. More studies are needed to unravel the genetic basis of
ART immunological non-response.
© 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Espan˜a, S.L.U. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Introduction
The introduction of antiretroviral therapy (ART) in the clinical
practice saved millions of lives from acquired immunodefi-
ciency syndrome (AIDS) related deaths, which is the result of
chronic infection by the human immunodeficiency virus type
1 (HIV-1).1,2 ART regimens are combinations of three drugs.
For several years, the first-line regimens usually included two
nucleoside analog reverse transcriptase inhibitors (NRTIs) and
a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a
protease inhibitor (PI). Currently, integrase inhibitors (INI) are
being recommended instead of NNRTI or PI, with the objective
of suppressing viral replication.3,4
With viral suppression, replenishment of lost CD4+ T cells
typically happens in a biphasic manner: a rapid proliferation
during the first three to six months of ART, caused by mem-
ory T cells redistribution, followed by a slower proliferation
phase by naïve T cells production by the thymus.5 However,
some patients do not present optimal CD4+ T cells gains, even
with persistent viral suppression. This phenomenon is named
immunological failure or immunological non-response, and it
is associated with higher risk of non-AIDS cardiovascular dis-
ease, liver and kidney disorders, in addition to early aging.6–9
The immunological non-response has not yet been com-
pletely elucidated. Older age, male sex, advanced HIV-1
infection at treatment start and coinfections by other
viruses are some known risk factors,5,10,11 but the influ-
ence of host genetic component is still debated. Promising
genetic candidates include genes involved in antiretroviral
drugs pharmacodynamic pathways12,13 and genes involved in
immune functions (inflammation, apoptosis) and homeosta-
sis, such as the interleukins IL2, IL7 and IL15,which coordinate
T cell proliferation.14
Our hypothesis was that genetic variation in these genes
would affect the distribution of antiretroviral drugs, possibly
favoring residual (undetected) virus replication, which in turn
would drive immune activation and immune cell death, ham-
pering CD4+ T cell recovery. Simultaneously, single nucleotide
polymorphisms (SNPs) in the immune system genes would
favor this increased cell activation, increased apoptosis or
decreased cell proliferation, leading to suboptimal immuno-
logical response to ART. So, we aimed at identifying genetic
variants associated with delayed CD4+ T cell counts recovery
to quasi-normal or normal levels.
Material and methods
Subjects
A total of 176 (91 females, 51.7% and 85 males, 48.3%) HIV-1
infected patients receiving care at Instituto de Medicina Inte-
gral Professor Fernando Figueira (IMIP)were recruited in Recife
and nearby cities, Pernambuco state, Northeast Brazil, for a
case–control, observational study between 2011 and 2015.
Inclusion criteria were: age over 18 years old, not report-
ing illicit drug use, and not being pregnant. Informed consent
to participate in the study and to have the medical charts
reviewed was obtained from all included participants. A
peripheral blood sample was collected from each patient. IMIP
ResearchEthicsCommittee approved the studyprotocol (num-
ber 3629-13).
Each patient answered a standard questionnaire about sex,
age and age at ART start, socioeconomic status, smoking, and
drinking habits. The data extracted from medical charts cov-
ered the whole period between the first and last plasma viral
load (pVL) and CD4+ T cell absolute counts and percentage
(relative to all white blood cells) measurements (retrospective
follow-up).
Other abstracted data included ART regimens received and
their refill prescriptions and serological status for the follow-
ing etiologic agents: HBV, HCV, CMV (IgG and IgM), HTLV-1/2,
Toxoplasma gondii (IgG and IgM) and Treponema pallidum (VDRL)
and occasional AIDS-defining conditions following the Cen-
ters for Disease Control (CDC) 1993 Revised Classification
System.15
Patient classification
All patients achieved persistent viral suppression, which
was defined as maintaining undetectable (also known as
“target not detected”) plasma viral load measurements
(pVL<50 copies/mL as measured by RT-PCR). Current pVL
quantification methods adopted in Brazil, such as Abbott
RealTime HIV-1 Viral Load Assay16 have detection lim-
its of 40 copies/mL, but since our sample is retrospective,
we adopted the 50 copies threshold to account for mea-
surements using earlier methods. No patient presented
viral load rebound, which was defined as two consecutive
pVL>1000 copies/mL at any time after initial suppression,
according to Brazil’s Ministry of Health’s guidelines at the time
of patients’ recruitment.17 In the study setting, pVL measure-
ments, CD4+ T cell counts and other laboratory tests were
generally performed every three or four months, at the physi-
cian’s discretion.
Immunologic response was defined as CD4+ T cell
percentage achieving 30% or higher for two consecutive
measurements during follow-up and immunological non-
response if otherwise, following Brazilian Ministry of Health’s
guidelines.17 If a patient already had pre-ART CD4+ T cell per-
centages >30% (early start patients), immunological response
was considered as an absolute gain of 200 cells/L, according
to a previous study.5 CD4+ T cell percentages were preferred
instead of absolute counts because percentages are less vari-
able over time.18
Thus, 67 patients were categorized into immunological
non-response and 109 into immunological response groups
and their follow-up duration was recorded for further survival
analysis.
SNPs selection and genotyping
Genes and SNPs were selected through literature search
and functional criteria. We selected 46 SNPs distributed
in 19 genes of antiretroviral pharmacodynamic pathways:
ABCB1 (rs1128503, rs2214102, rs2235048 and rs3842), ABCC1
(rs129081, rs113264879, rs4148380, rs8056298, rs212091 and
rs16967632), ABCG2 (rs115770495, rs1448784 and rs2231142),
CYP1A2 (rs762551), CYP2A6 (rs8192726), CYP2B6 (rs8192709,
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rs28399499, rs34097093, rs28399502, rs707265 and rs1042389),
CYP3A4 (rs4646437), SLC22A6 (rs11568629, rs11568628 and
rs4149170) andNR1I3 (rs3003596)19–27 and immunological acti-
vation and homeostasis: CCL5 (rs2107538), FAS (rs2234767 and
rs1800682), IFNG (rs2069709), IL10 (rs2222202, rs1800871 and
rs1800890), IL10RA (rs3135932 and rs9610), IL15 (rs10519613
and rs10833), IL1B (rs16944), IL2 (rs2069762), IL4 (rs2243250),
IL7R (rs1494555, rs11567762, rs6897932, rs3822731, rs987106
and rs3194051).28–30
Additionally, 48 SNPs that served as ancestry informative
markers (AIMs) were also genotyped (all variants are listed on
Supplementary Table 1). Briefly, these SNPs help estimating
ancestry proportions in admixed populations such as the one
enrolled in our study, controlling for population structure and
reducing bias during genetic association analysis.31 Genomic
DNA was extracted through Promega
®
Wizard Genomic DNA
Purification Kit (Fitchburg, Wisconsin, USA), following man-
ufacturer’s instructions. Genotyping was performed through
VeraCode
®
platform of GoldenGate
®
Illumina Inc (San Diego,
California, USA) technology, followingmanufacturer’s instruc-
tions.
Raw genotyping data were extracted with Illumina
®
Genome Studio 2.0 software and exported to an Excel
®
work-
sheet. After processing, the dataset was exported into PLINK
software, version 1.9032 to perform quality control (QC) filter-
ing. Samples and variants with less than 90% global call rates
were removed from further analysis. Variants with signifi-
cant departure from Hardy–Weinberg equilibrium were also
removed, using an exact test with p-value<0.001 as threshold.
Ancestry proportion estimation
We used ADMIXTURE software33 to carry out a “supervised
analysis” allowing estimation of ancestry proportions in
our admixed samples, using 2000 bootstrap steps with the
AIMs panel mentioned above. The calculations were made
assuming three different ancestral populations (K=3; African,
Amerindian, and European).
Statistical analysis
Comparisons between immune non-response and immune
response groups were performed through Fisher’s exact test
or Chi-square test for categorical variables (sex, ART regimens,
genetic association tests) and Mann–Whitney test for contin-
uous variables (age and pre-ART CD4+ T cell absolute counts).
Age at ART start was also treated as a categorical variable with
four strata: 18–29 years, 29–39 years, 39–49 years, and 49 years
or more.
Additionally, univariate survival analyses were performed
through Kaplan–Meier survival probability estimator hav-
ing time to immune response as the dependent variable.
Estimators for each variable were then compared through
Cox–Mantel log rank test to assess if they exerted statistically
significant influence on the dependent variable.
Alleles and genotypes counts and frequencies
were obtained through direct counting. Compliance to
Hardy–Weinberg equilibrium was also assessed through
Chi-square test. All tests were two-sided. The variables (with
the exception of coinfections serological status, smoking and
drinking habits – data not shown here- for the last two –
and AIDS-defining conditions were not included in further
analyses due to high prevalence of missing data – over 10%
of data points, to avoid the introduction of bias into the
model) were included in a multivariate survival analysis Cox
proportional hazards model to assess which variables would
independently influence immune response. All analyses were
performed with R software, version 3.3.1.34
Results
Patients’ characteristics
The individuals in our sample presented a major European
ancestry contribution (mean proportion 55.2±18.5%), fol-
lowed by African (32.3±16.4%) and Amerindian (12.4±10.5%),
as expected, due to our previous works with other samples of
the same general population.31
The median age at treatment start was 33 years old
(interquartile range, IQR=27–39), and the patients tended to
start ART with relatively low CD4+ T cell counts/L of periph-
eral whole blood (median=272, IQR=127.5–432.5), and 29.5%
of the patients started with less than 200 cells/L. In contrast,
only 10.8% of the patients started with more than 500 cells/L.
Similarly, CD4 percentages relative to total lymphocyte count
were also low, (median=19.4%, IQR=12.4–27.5%), and only
13.1% of the patients started therapy with more than 30%
CD4+ T cells. Most AIDS-defining conditions diagnoses were
not available (67.6%) in the medical charts, but at least 22.1%
of the patients started ART with C stage conditions.
Regarding ART regimens, the majority of the patients
received zidovudine+ lamivudine (AZT+3TC) as first lineNRTI
backbone following the guidelines at that moment (68.2%),
followed by tenofovir + lamivudine (TDF+3TC, 19.9%) and aba-
cavir + lamivudine (ABC+3TC, 0.6%). AZT monotherapy was
the starting treatment for 2.8% of the patients, and informa-
tion on the first regimen received was not available for 8.5%
of the patients. The third drug option was mostly a NNRTI
(53.5%), such as efavirenz (EFZ) or nevirapine (NVP), and riton-
avir boosted PI such as lopinavir or atazanavir (LPV/r or ATV/r)
prescribed to 35.2% of the patients. Table 1 also displays uni-
variate comparison of patients’ characteristics.
Univariate analysis of patients’ characteristics
Males had more than two-fold increased risk of present-
ing immunological non-response (61.2% non-responders and
40.4% responders; odds ratio (OR) = 2.32; 95% CI = 1.20–4.56;
p=0.01). Both groups had similar ages at treatment start
(median 34 years and 33 years, respectively; p=0.45). As
expected, non-responders started treatment with lower abso-
lute CD4+ T cell count than responders (median 179 cells/L
vs. 342.5 cells/L, respectively, p<0.001), and most non-
responders started therapy with less than 200 cells/L (49.2%
vs. 17.4%; p<0.001). Patients in both groups had similar ances-
try backgrounds (mean African ancestry proportion 33.5% in
non-responders vs. 31.7% in responders, p=0.68).
Non-responders started treatment with more advanced
disease than responders; 31.3% of non-responders presented
C (AIDS-indicator conditions) CDC system stage vs. 16.5% of
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Table 1 – Pre-treatment characteristics of study subjects according to antiretroviral therapy immunologic response.
Variables Total (n=176) Immunologic
non-responders
(n=67)
Immunologic
responders
(n=109)
Univariate
analysis
Sex, n (%)
Females 91 (51.7) 26 (38.8) 65 (59.6) Reference
Males 85 (48.3) 41 (61.2) 44 (40.4) OR=2.32 (95% CI = 1.20–4.56); p=0.01
Ancestry proportions estimated by AIMs, mean percentage (SD)
African 32.3 (16.4) 33.5 (18.5) 31.7 (15.0)
Amerindian 12.4 (10.5) 12.3 (9.2) 12.5 (11.2) W=3487; p=0.68
European 55.2 (18.5) 54.3 (19.8) 55.8 (17.7)
Age at ART start date
Median (IQR) 33 (27–39) 34 (28–40) 33 (27–38) W=3897.5; p=0.45
Pre-ART CD4+ T cell counts, cells/L of peripheral whole blood
Median (IQR) 272 (127.5–432.5) 179 (94.5–279.5) 342.5 (228.2–487) W=1268; p<0.001
By categories, n (%)
Not available 37 (21.0) 12 (18.0) 25 (22.9) (Not included in the comparison)
Less than 200 52 (29.5) 33 (49.2) 19 (17.4) X2 = 26.4; df = 3; p<0.001
Between 200 and 350 39 (22.2) 13 (19.4) 26 (23.9)
Between 350 and 500 29 (16.5) 9 (13.4) 20 (18.4)
Over 500 19 (10.8) 0 (0.0) 19 (17.4)
Pre-ART CD4+ T cell percentages, relative to total lymphocyte count
Median (IQR) 19.4 (12.4–27.5) 11.8 (7.0–17.0) 23.8 (18.1–30.2) W=643; p<0.001
By categories, n (%)
Not available 48 (27.3) 23 (34.3) 25 (22.9) (Not included in the comparison)
30% or less 105 (59.6) 43 (64.2) 62 (56.9) X2 = 9.6; df = 1; p=0.002
Over 30% 23 (13.1) 1 (1.5) 22 (20.2)
Pre-ART AIDS-defining conditions according to CDC classification system, frequency (%)
Not available 119 (67.6) 40 (59.7) 79 (72.5) (Not included in the comparison)
A stage 1 (0.6) 0 (0.0) 1 (0.9)
B stage 17 (9.7) 6 (9.0) 11 (10.1) X2 = 2.6; df = 2; p=0.28
C stage 39 (22.1) 21 (31.3) 18 (16.5)
First ART regimens, frequency (%)
Not available 15 (8.5) 6 (8.9) 9 (8.2) (Not included in the comparison)
Monotherapy 5 (2.8) 1 (1.5) 4 (3.7)
Detailed regimens: [NRTI]+3TC [third option]
ABC+3TC EFZ 1 (0.6) 1 (1.5) 0 (0.0) X2 = 12.3;
df = 9;
p=0.20
AZT+3TC ATV/r 6 (3.4) 2 (3.0) 4 (3.7)
AZT+3TC EFZ 55 (31.3) 22 (32.8) 33 (30.3)
AZT+3TC FPV/r 1 (0.6) 1 (1.5) 0 (0.0)
AZT+3TC IDV/r 1 (0.6) 1 (1.5) 0 (0.0)
AZT+3TC LPV/r 49 (27.8) 17 (25.4) 32 (29.3)
AZT+3TC NVP 8 (4.5) 1 (1.5) 7 (6.4)
TDF+3TC ATV/r 4 (2.3) 0 (0.0) 4 (3.7)
TDF+3TC EFZ 30 (17.0) 15 (22.4) 15 (13.8)
TDF+3TC LPV/r 1 (0.6) 0 (0.0) 1 (0.9)
ART regimens, stratified by [third option]
NNTRI 94 (53.5) 39 (58.2) 55 (50.5) Reference
PI/r 62 (35.2) 21 (31.4) 41 (37.6) OR=0.72 (95% CI = 0.35–1.48); p=0.40
[NRTI] choice alongside 3TC
ABC 1 (0.6) 1 (1.5) 0 (0.0) (Not included in the comparison)
AZT 120 (68.2) 44 (65.7) 76 (69.7) Reference
TDF 35 (19.9) 15 (22.4) 20 (16.7) OR=1.29 (95% CI = 0.56–2.97); p=0.56
Bold values were statistically significant values, p<0.05.
3TC, lamivudine; 95% CI, 95% confidence interval; ABC, abacavir; AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy;
ATV/r, ritonavir-boosted atazanavir; CDC, Center for Disease Control (USA); df, degrees of freedom; EFZ, efavirenz; FPV/r, ritonavir-boosted
fosamprenavir; IDV/r, ritonavir-boosted indinavir; IQR, interquartile range; LPV/r, ritonavir-boosted lopinavir; NNRTI, non-nucleoside analog
reverse transcriptase inhibitor; NRTI, nucleoside analog reverse transcriptase inhibitor; NVP, nevirapine; OR, odds ratio; p, p-value; PI, protease
inhibitor; SD, standard deviation; TDF, tenofovir; W, Mann–Whitney test statistic; X2, chi-squared test statistic.
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Table 2 – Post-treatment immunologic response with corresponding observable follow-up time on therapy according to
study groups.
Variables Total (n=176) Immunologic
non-responders
(n=67)
Immunologic
responders
(n=109)
Univariate
analysis
Observed time in therapy (months)
Median (IQR) 33 (19.8–60.5) 32 (17–51) 33 (21–81) W=3177; p=0.15
CD4+ T cell counts, cells/L
Median (IQR) 578.5 (393.2–807.5) 380 (280–487) 715 (545–900) W=901.5; p<0.001
CD4+ T cell percentages, relative to total lymphocyte count
Median (IQR) 36.7 (23.0–35.8) 22 (16.5–26.0) 34.3 (30.8–39.3) W=390; p<0.001
Events of detectable plasma viral load (pVL≥50 and <1000 copies/mL) at any time following viral suppression
Median number of detectable measurements (IQR) 1 (0–3) 1 (0–4) 1 (0–3) W=2816.5; p=0.74
Percentage of detectable measurements (IQR) 7.4 (0.0–18.2) 10.0 (0–23.1) 6.3 (0–16.7) W=2955.5; p=0.37
IQR, interquartile range; p, p-value; W, Mann–Whitney test statistic.
responders, although the difference did not reach statistical
significance (p=0.28).
Patients started with similar first-line ART regimens
(p=0.20). There was neither difference in the frequency of
NNRTI and PI (p=0.40) as third drug nor AZT+3TC and
TDF+3TC (p=0.56) as backbones.
The median time on treatment and of laboratory tests was
33 months (IQR=19.8–60.5). As expected, ART greatly bene-
fited patients. Aggregating laboratory measurements from the
last observation in each patient, the median CD4+ T cell count
rose to 578.5 cells//L of blood (IQR=393.2–807.5), an incre-
ment by nearly 113% from pre-ART values mentioned above
(p<0.001). Similarly, CD4+ T cell percentages rose to 36.7%
(IQR=23.0–35.8), an increment by nearly 62% (p<0.001). These
post-ART changes are summarized in Table 2.
The median time to achieve immunologic response was
47 months (95% CI = 36–64). The time for men and women to
achieve immunologic response was almost the same with a
median time of 48 months (95% CI = 36–110) for men and 46
months (95% CI = 30–66) for women (p=0.42). Age groups at
ART start was neither associated with time until immuno-
logic response (p=0.67). Similarly, use of AZT instead of TDF
(p=0.11) or PIs instead of NNRTIs as third drug (p=0.14) onART
regimens also did not influence time until response.
Serological tests results were not recorded in medical
charts of the majority of patients. Although about 65% of the
patients did not results for CMV and toxoplasmosis infections,
the prevalence of positive IgGwas 33.5% for CMV and 27.8% for
toxoplasmosis. Syphilis VDRL positivity rate was 13.6% of the
total (34.7% untested); 25.0% were immune to hepatitis B virus
(HBV) due to vaccination, 5.7%due tonatural infection, and the
remaining 26.1%were susceptible, but none presented chronic
infection (43.2% untested). No patient was positive for anti-
HTLV-1/2 (79.5% untested); a single case of anti-HCV positive
was detected (47.7% untested). Table 3 details the serological
tests results.
Genotyping quality control (QC), ancestry estimation and
genetic association testing
Two candidate SNPs, rs11568629 (SLC22A6) and rs16967632
(ABCC1) and four AIMs did not pass genotyping QC and were
removed from further analysis. Other variant, rs34097093
(CYP2B6), was also removed because all individuals in the sam-
ple had the same genotype (one of the alleles was fixed). The
remaining allele and genotype frequencies were all in con-
formity to Hardy–Weinberg equilibrium according to PLINK
software exact test. All frequencies and global call rates are
displayed in Supplementary Table 2. Therefore, further anal-
yses were performed using the remaining 43 candidate SNPs
and 44 AIMs.
Five SNPs presented statistic association with immuno-
logical outcome. Three minor alleles were more frequent
in non-responders than responders: rs2243250 (IL4) A allele
(48.0% vs. 37.0%, p=0.04), rs1128503 (ABCB1) A allele (40.0% vs.
28.0%, p=0.03) and rs707265 (CYP2B6) A allele (40.0% vs. 23.0%,
p=0.02), whereas the other twoweremore frequent in respon-
ders: rs2069762 (IL2) C allele (15.0% vs. 30.0%; p=0.004) and
rs4646437 (CYP3A4) A allele (26.0% vs. 34.0%; p=0.04). Allele,
genotype frequencies and statistical analyses for these five
SNPs are displayed in Table 4 and Supplementary Table 3 dis-
plays all genetic association results.
Since non-responders and responders had similar ances-
try proportions (for example, mean African contribution
33.5±18.5% vs. 31.7±15.0%, respectively; p=0.68), we believe
that there is no hidden genetic structure biasing the genetic
association analysis. As mentioned in the next session, indi-
vidual African genetic ancestry contributions were included
in the multivariate Cox proportional hazards model for an
additional “genomic control”.35
Multivariate analysis
The multivariate Cox proportional hazards analysis sug-
gested that starting ART with less than 200 CD4+ T cells/L,
IL2 rs2069762 genotypes, ABCB1 rs1128503 genotypes and
PI/r use were significantly associated with time to immune
response.
Individuals starting ART with less than 200 CD4+ T
cells/L had 61% lower chance of achieving immuno-
logic response when compared with those who started
ART with more than 200 CD4+ T cells/L (HR=0.39, 95%
CI = 0.21–0.74, adjusted p=0.004). IL2 rs2069762 C/C geno-
type had an eight-fold higher probability of achieving
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Table 3 – Coinfections serological status of study subjects according to antiretroviral therapy immunologic response.
Etiologic agent Total
n=176 (%)
Immunologic
non-responders
n=67 (%)
Immunologic
responders
n=109 (%)
Cytomegalovirus (CMV)
IgM test
Untested 115 (65.4) 53 (79.1) 62 (56.9)
Negative 59 (33.5) 14 (20.9) 45 (41.3)
Positive 2 (1.1) 0 (0.0) 2 (1.8)
IgG test
Untested 115 (65.4) 53 (79.1) 62 (56.9)
Negative 2 (1.1) 0 (0.0) 22 (1.8)
Positive 59 (33.5) 14 (20.9) 45 (41.3)
Hepatitis B virus (HBV)
Untested 76 (43.2) 35 (52.2) 41 (37.6)
Susceptible 46 (26.1) 13 (19.4) 33 (30.3)
Chronic infection 0 (0.0) 0 (0.0) 0 (0.0)
Immune due to natural infection 10 (5.7) 4 (6.0) 6 (5.5)
Immune due to vaccination 44 (25.0) 15 (22.4) 29 (26.6)
Hepatitis C virus (HCV)
Untested 84 (47.7) 36 (53.7) 48 (44.0)
Negative 91 (51.7) 31 (46.3) 60 (55.0)
Positive 1 (0.6) 0 (0.0) 1 (1.0)
Human T-lymphotropic virus type 1 or 2 (HTLV-1/2)
Untested 140 (79.5) 60 (89.5) 80 (73.3)
Negative 36 (20.5) 7 (10.5) 29 (26.6)
Positive 0 (0.0) 0 (0.0) 0 (0.0)
Toxoplasma gondii
IgM test
Untested 115 (65.3) 52 (77.6) 63 (57.8)
Negative 61 (34.7) 15 (22.4) 46 (42.2)
Positive 0 (0.0) 0 (0.0) 0 (0.0)
IgG test
Untested 115 (65.3) 52 (77.6) 63 (57.8)
Negative 12 (6.8) 5 (7.5) 7 (6.4)
Positive 49 (27.8) 10 (14.9) 39 (35.8)
Treponema pallidum (VDRL test)
Untested 61 (34.7) 32 (47.8) 29 (26.6)
Negative 91 (51.7) 24 (35.8) 67 (61.5)
Positive 24 (13.6) 11 (16.4) 13 (11.9)
IgM, immunoglobulin M; IgG, immunoglobulin G.
immunologic response when compared to A/A genotype
(HR=8.60, 95% CI = 2.06–35.89, adjusted p=0.003) during the
follow-up period. ABCB1 rs1128503 A/A genotype was asso-
ciated with 71% lower chance of achieving immunologic
response when compared with G/G genotype (HR=0.29, 95%
CI = 0.15–0.58, adjusted p=0.0004). Using an ART regimen
containing PI/r had almost two-fold higher probability of
achieving immunologic response (HR=1.89, 95%CI = 1.03–3.50,
adjusted p=0.04).
On the other hand, sex (adjusted p=0.51), genetic back-
ground (adjusted p=0.85), age at treatment start (adjusted
p=0.82), IL4 rs2243250, CYP3A4 and CYP2B6 SNPs, use of AZT
as NRTI backbone, and events of detectable pVL following viral
suppression were not significantly associated with probability
to immune response on multivariate analysis. The multivari-
ate analysis results are summarized in Table 5.
Discussion
ART, when taken correctly with good adherence, sup-
presses HIV-1 replication, decrease immune activation,
favors immune recovery, and protects against opportunis-
tic infections.36,37 However, some patients fail to recover
CD4+ T cell numbers to normal or quasi-normal levels
(immunological failure or non-response), being at risk for
non-AIDS diseases, such as cardiovascular, kidney and liver
disorders5 and premature aging.8,9 Thus, we performed a
genetic association study through survival analysis to assess
if polymorphisms in antiretroviral drugs pharmacodynamic
pathways and immune system homeostasis were related with
immunological failure in a sample from Recife, Northeast
Brazil.
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Table 4 – Allele and genotype frequencies of variants showing statistically significant genetic association with immunologic outcome.
a SNP Type Alleles Gene Gene
func-
tion/pathway
Allele and genotype frequencies X2 DF p
Immunologic non-responders Immunologic responders
A1 A2 A2 (%) A1/A1 (%) A1/A2 (%) A2/A2 (%) A2 (%) A1/A1 (%) A1/A2 (%) A2/A2 (%)
26 rs2069762 Upstream gene
region
A C IL2 Regulates T and B
lymphocytes
proliferation
20
(15.0)
47
(70.0)
20
(30.0)
0
(0.0)
65
(30.0)
49
(45.0)
53
(49.0)
6
(6.0)
10
.9
2 0
.004
38 rs2243250 Upstream gene
region
G A IL4 Immunoregulation 59
(48.0)
13
(21.0)
39
(63.0)
10
(16.0)
76
(37.0)
39
(38.0)
50
(49.0)
13
(13.0)
6
.7
2 0
.04
46 rs1128503 Synonymous
(Gly412Gly)
G A ABCB1 Membrane
transport,
antiretroviral drugs
efflux
53
(40.0)
26
(39.0)
29
(43.0)
12
(18.0)
62
(28.0)
57
(52.0)
42
(39.0)
10
(9.0)
7
.3
2 0
.03
48 rs4646437 Intronic G A CYP3A4 Antiretroviral drugs
metabolism
35
(26.0)
35
(52.0)
29
(43.0)
3
(4.0)
75
(34.0)
53
(49.0)
37
(34.0)
19
(17.0)
6
.2
2 0
.04
89 rs707265 3′ untranslated
region
G A CYP2B6 Antiretroviral drugs
metabolism
54
(40.0)
22
(33.0)
36
(54.0)
9
(13.0)
50
(23.0)
63
(58.0)
40
(37.0)
5
(5.0)
8
.3
2 0
.02
a Order (by chromosome and genomic position) in which the candidate and ancestry informative markers are listed on the Supplementary Tables; DF, degrees of freedom; X2, value of chi-squared
statistic from chi-square test of independence; p, p-value.
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Table 5 – Cox proportional hazards multivariate model for predicting time to immune response.
Variable Hazard ratio 95% confidence
interval. lower
limit
95% confidence
interval. upper
limit
Adjusted p
Male sex 1.2501 0.6477 2.4130 0.51
African genetic background (%) 1.2388 0.1348 11.3837 0.85
Age at ART start 1.0050 0.9627 1.0492 0.82
Start ART with less than 200 CD4+ T cells/L of blood 0.3928 0.2081 0.7413 0.004
IL2 SNP
rs2069762 A/A Reference
rs2069762 A/C genotype 0.6767 0.3709 1.2349 0.20
rs2069762 C/C genotype 8.5971 2.0590 35.8958 0.003
IL4 SNP
rs2243250 G/G genotype Reference
rs2243250 A/G genotype 0.5370 0.2290 1.2589 0.15
rs2243250 A/A genotype 0.7983 0.4057 1.5709 0.51
ABCB1 SNP
rs1128503 G/G genotype Reference
rs1128503 A/G genotype 0.4941 0.2060 1.1851 0.11
rs1128503 A/A genotype 0.2933 0.1479 0.5816 0.0004
CYP3A4 SNP
rs4646437 G/G genotype Reference
rs4646437 A/G genotype 1.9287 0.7274 5.1134 0.19
rs4646437 A/A genotype 0.9919 0.5277 1.8646 0.98
CYP2B6 SNP
rs707265 G/G genotype Reference
rs707265 A/G genotype 0.3201 0.0660 1.5532 0.16
rs707265 A/A genotype 0.7842 0.4252 1.4463 0.44
Regimen containing AZT as NRTI option 0.8751 0.3714 2.0621 0.76
Regimen containing PI/r as third option 1.8951 1.0258 3.5010 0.04
Events of detectable plasma viral load (pVL≥50 copies/mL) 0.9953 0.9727 1.0183 0.68
ART, antiretroviral therapy; SNP, single nucleotide polymorphism; NRTI, nucleoside analog reverse transcriptase inhibitor; p, p-value; PI/r,
protease inhibitor boosted with ritonavir.
The observed prevalence of immunological non-response
was 38.1%, which was is in concordance with some esti-
mates found in the literature, ranging between 10% and
40%.38
Our sample comprises people with lower socioeconomic
status with less access to sexual education and healthcare.
The diagnosis of HIV-1 infection in this population is usually
delayed or very delayed and, therefore, ART tend to be initi-
atedwhenabsoluteCD4+Tcells counts are low,with advanced
disease and presenting symptoms of opportunistic infections.
A very compromised immune system by chronic HIV-1 infec-
tion predisposes to immunologic non-response,39 and indeed
we observed that non-responders begun treatment with lower
absolute CD4+ T cell counts, with almost half of them starting
treatment with less than 200 cells/L.
Previous reviews also reported that male sex, older age38
and HCV coinfection are risk factors for immune non-
response.40,41 We only found an association between male
sex and immune failure in univariate analysis, but this asso-
ciation was lost in multivariate survival analysis. We also
assessed HCV infection status alongside other agents (CMV,
HBV, HTLV-1/2, toxoplasmosis, and syphilis), but the high
prevalence of untested subjects for most of these infections
hindered further analysis, since it could bias the results with
sample size restriction. However, we believe that HCV and
HTLV-1/2 had very low prevalence in our sample (no case of
positive HTLV-1/2 and a single case of HCV infection among
those available), and therefore they are unlikely to play a
role on immunological outcome in the present study sam-
ple our sample. Moreover, no case of chronic HBV-infection
was detected, whereas there were some individuals with anti-
HBV immunity due to past infections and vaccination. We
also found some individuals with latent CMV infection (pos-
itive IgG), a known causative agent of persistent immune
activation,42 which can cause immune system exhaustion,43
but we cannot affirm if it was a factor favoring immune non-
response in our sample, as it would be too speculative, since
our serological data status was mostly lacking, as discussed
above.
Sex and pre-ART CD4+ T cell counts were the only non-
genetic differences between our study groups, since the
individuals in our sample had similar ethnic backgrounds
(as estimated by AIMs), and ART regimen types and distri-
bution were alike between groups. Therefore, we expected to
find genetic risk factors to immunologic non-response. We
genotyped 46 candidate SNPs located in genes involved on
antiretroviral drugs metabolism and transport and in genes
involved on immune response. We found five SNPs associ-
ated – three with susceptibility to non-response and two with
favorable response.
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Two of the three SNPs associated with non-response are
located in genes related to drug metabolism: CYP2B6 and
ABCB1. The former is a protein fromamembranehemoprotein
superfamily that is collectively involved in the metabolism of
antiretroviral drugs and several others12 and the latter is a
membrane active transport protein that ejects antiretroviral
drugs from cells.44 The third is located at IL4 gene, which is
involved in a polyfunctional immunoregulatory signal.45 One
of two SNPs associated with favorable response is located at
a gene related to immune system homeostasis, important for
T and B cells proliferation, IL2,46 and the other is located in
CYP3A4, another gene of drug-metabolizing CYP450 protein.12
We expected that SNPs in these genes would work in
concert to affect gene function, altering distribution of
antiretroviral drugs, and having deleterious consequences
on immune function, leading to suboptimal immunological
response to ART. However, all genetic associations were lost
significance after multivariate survival analysis modeling. As
other authors have not found associations focusing on the
same or similar genes47 while others did have48 (for a review
of previous genetic association studies, refer to38), more stud-
ies are necessary to unravel the genetic component of ART
immunological non-response.
In conclusion, we performed a genetic association study
looking for genetic variants that would explain suboptimal
gains of CD4+ T cell counts in some individuals in a ret-
rospective observational sample of individuals living with
HIV-1 receiving ART from Northeast Brazil, and elaborated a
multivariate statistical model for the prediction of immune
response. More studies are necessary, in order to continu-
ously refine the predictive model of immunological response,
consequently improving HIV-1 infection care, and perhaps
preventing complications seceondary to immunological non-
response, such as systemic diseases and/or premature aging.
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